Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

NCT06650423 ·Status: RECRUITING

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026 ·Status: COMPLETED

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer

NCT03843346 ·Status: COMPLETED

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172 ·Status: COMPLETED ·Phase: PHASE2

Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

NCT06800612 ·Status: RECRUITING

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

NCT00434031 ·Status: WITHDRAWN ·Phase: PHASE2

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

NCT04614194 ·Status: RECRUITING ·Phase: PHASE2

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

NCT07213206 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy

NCT04133207 ·Status: COMPLETED

Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy

NCT01645059 ·Status: COMPLETED

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

NCT06259929 ·Status: RECRUITING ·Phase: PHASE2

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

NCT06176534 ·Status: RECRUITING ·Phase: PHASE2

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

NCT06996093 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

NCT03926091 ·Status: RECRUITING ·Phase: PHASE3

Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)

NCT06129786 ·Status: RECRUITING

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

NCT06040593 ·Status: COMPLETED

A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer

NCT06343181 ·Status: RECRUITING

A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

NCT07340658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

NCT01049425 ·Status: COMPLETED ·Phase: PHASE3

The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

NCT04753177 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

NCT05673850 ·Status: COMPLETED

Endocrine Disruptors and Life STILe in Breast Cancer Development

NCT05748353 ·Status: ACTIVE_NOT_RECRUITING